美洛西林-舒巴坦对不同呼吸系统和泌尿生殖系统感染患者的临床疗效比较

目的:比较美洛西林-舒巴坦对不同呼吸系统和泌尿生殖系统感染患者的疗效及其对临床各指标的影响。方法:抽取2017年11月-2018年11月间收治的不同呼吸系统和泌尿生殖系统感染患者160例资料;按注射用美洛西林-舒巴坦治疗疾病的不同将其分为呼吸系统感染患者129例和泌尿生殖系统感染患者31例;分析其对不同疾病患者的临床疗效及其对各症状指标改善的影响。结果:呼吸系统感染患者的总有效率和泌尿生殖系统感染患者的总有效率分别为92.25%和90.32%;与治疗前相比,治疗后各临床指标均得到显著改善;不良反应症状轻其发生率仅为1.88%。结论:对于呼吸系统感染和泌尿生殖系统感染患者,采用美洛西林-舒巴坦治疗具有良好效果,且具有较高的安全性。

Comparation of Efficacies of Mezlocillin-Sulbactam in Patients with Respiratory and Urogenital Infections

Objective:To compare the efficacies of mezlocillin-sulbactam in patients with different respiratory and urogenital infections and its influence on clinical indicators.Methods:Clinical data of 160 patients with different respiratory and urogenital infections admitted from November 2017 to November 2018 were extracted.According to the different diseases treated with meloxicillin-sulbactam for injection,129 patients with respiratory system infection and 31 patients with urogenital system infection were divided.The clinical efficacies of patients with different diseases and their influence on the improvement of various symptom indicators were analyzed.Results:The total effective rate of patients with respiratory system infection and patients with urogenital system infection were 92.25%and 90.32%,respectively.Compared with that before treatment,all the clinical indexes were significantly improved after treatment.The incidence of mild adverse drug reactions was only 1.88%.Conclusion:For patients with respiratory and urogenital system infection,the medication of meloxicillin-sulbactam has a good efficacy,and it also has a higher security.